Sanofi is working on two vaccine projects to prevent COVID-19 - the disease caused by the new coronavirus - and is exploring a number of manufacturing options, including to ensure that the program succeeds. Drugmakers are racing to develop treatments and vaccines for the highly contagious coronovirus that has killed more than 255,000 people worldwide, infecting more than 3.6 million and devastating economies globally. At the same time, 10 of the more than 100 vaccine candidates for development have reached the clinical trial stage, according to the Milken Institute, a California-based think tank. Sanofi will bring in a protein antigen - a molecule designed to trigger an immune response in the body - based on a platform it uses for its influenza vaccine Flublok.
GSK will contribute one of its approved subsidiaries, which works by boosting the immune response to produce more antibodies and long-lasting immunity. Sanofi Pasteur executives told Reuters the company was in early-stage in September. The test is expected to begin, involving hundreds of subjects. While Phase I vaccine trials typically test for safety A small number of healthy volunteers are present to test, Sanofi said, that he had chosen soon to secure a greater number of robust data. "We have envisioned Phase I, actually several hundreds of topics, So this is actually a Phase I / II trial, "said John Shiver, Head of Sanofi Vaccine Research. In addition to finding the right vaccine, a significant challenge is building on a large scale and Lies in delivering the product globally. "We will compare different doses of the vaccine and this is very important.
A BIT 'TRICKY' Vaccine Executive Vice President David Lowe said that Sanofi has begun preliminary discussions with countries on the mechanism to pre-order the vaccine, if it works, "the legal details should still work with GSK." When you partner with another company, it is a difficult thing, ”he said, adding that talks were taking place with US officials as well as some European countries. Given BARDA's endorsement, doses produced at its US manufacturing facility are likely to first go to US patients, a possibility that has raised concerns in Europe. Asked whether Sanofi would meet its manufacturing pledges Will consider new cooperation, Lowe said, "Yes, if we come to the conclusion that we do not have enough capacity. On 24 April, Sanofi CEO Paul Hudson urged strengthening European coordination for a vaccine against the new coronovirus, which also slowed criticism of Europe. Sanofi of US-based Translation Bio Inc (TBIO.O) Is also working with another vaccine candidate based on messenger RNA technology (mRNA), in collaboration with BioNTech SE (22UAy) for experimental vaccines being developed by Pfizer Inc (PFE.N) Value. At the same time .F) and another Modern Inc. (MRNA.O) is developing in partnership with the US government. The mRNA technology instructs cells in the body to produce specific coronavirus proteins that then induce an immune response. With this, trials of that vaccine are expected to begin in the fourth quarter.
MediaTek launches Gaming processor Helio G85, know the specialty